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Abstract 
Alison Wagner 
Interactions between Intracerebral Human Immunodeficiency Virus-1 
Glycoprotein 120 and Systemic Heroin on Expression of Messenger Ribonucleic 
Acid (mRNA) of Inducible Nitric Oxide Synthase, Interleukin-1β, Tumor Necrosis 
Factor-α, and Cyclooxygenase-2 in Hippocampus and Cortex Brain Tissue of the 
Lewis Rat 
(Under the direction of Donald T. Lysle) 
 
Neurological complications caused by interactions of the immune system and the 
nervous system commonly occur in human immunodeficiency virus patients 
(HIV).  Intravenous drug users, including heroin users, have increased rates of 
HIV-induced pathology in the brain.  Glycoprotein 120 (gp120), a coat protein of 
HIV, has been implicated as a possible causative factor.  These experiments 
examined an in vivo model of HIV infection in the brain by injecting gp120 into 
the lateral ventricles of Lewis rats with and without systemic heroin 
administration.  The effects of gp120 and heroin were measured in expression of 
messenger RNA (mRNA) for the important proinflammatory mediators inducible 
nitric oxide synthase, interleukin-1β, tumor necrosis factor-α, and 
cyclooxygenase-2 in hippocampus and cortex tissue.  The results of these 
experiments indicate that heroin may uniquely alter the acute effects of gp120 in 
 ii
the rat brain on mRNA, allowing increased expression of interleukin-1β and 
inducible nitric oxide mRNA.
 iii
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I.  Introduction 
HIV/AIDS and Neurological Complications: Clinical Data 
During the 1980s, a puzzling condition that came to be known as acquired 
immunodeficiency syndrome (AIDS) began to become prevalent in the United 
States, particularly among intravenous drug users and homosexual men.   The 
first signs of the HIV epidemic in the United States were reported in the Morbidity 
and Mortality Weekly Report (MMWR) of Centers for Disease Control (CDC) in 
June of 1981 (CDC, 1981).  In 1983, it was discovered that AIDS was caused by 
a lentivirus, which is now known as human immunodeficiency virus (HIV) (Barre-
Sinoussi et al., 1983).  Today, 22 million people are known to have died from 
AIDS and AIDS-related complications, and 1 million more are infected with HIV in 
the United States alone as of 2006 (CDC, 2006).   
Neurological complications are common among HIV patients.  The 
terminology of these complications is complex and must be determined in order 
to understand the conditions fully (for review of terminology and diagnostic 
criteria, see Grant, Sacktor, & McArthur, 2005).  These neurological 
complications are collectively referred to as neurocognitive impairments.  HIV-
associated dementia (HAD) indicates a severe dementia in which the patient is 
unable to function in daily life due to cognitive impairments.  Mild cognitive motor 
disorder (MCMD) refers to deficits in 2 or more symptom areas that may affect 
 
daily life.  Included in these symptoms are neurocognitive decline, motor 
symptoms, and behavioral changes.  Another term often used in the literature is 
HIV encephalitis (HIVE), which simply refers to the physiological evidence of 
pathology believed to be associated with neurocognitive impairments in HIV.   
 In the early years of the HIV epidemic, these symptoms were severe and 
death usually occurred within onset of dementia.  Prevalence of dementia has 
decreased with the use of HAART, but the most drugs used in HAART do not 
cross the blood brain barrier (Flexner, 1998; Groothier & Levy, 1997).  Today, 
with the use of highly active antiretroviral therapy (HAART), neurocognitive 
impairments are more commonly diagnosed as the milder MCMD, which may be 
a more prevalent problem with the increased lifespan of HIV/AIDS patients 
(Grant, Sacktor, & McArthur, 2005).   
Neurocognitive impairments in HIV are associated with neuronal loss due 
to HIV infection of the brain (Everall, Luthert, & Lantos, 1991; Ketzler, Weis, 
Haug, & Budka, 1990).  Clinical studies have not been able to clearly elucidate 
the relationship between viral load in the brain and dementia or other indicators 
of neurocognitive deficits.  For instance, ribonucleic acid (RNA) levels of HIV 
were correlated with severity of dementia, but it was later found that levels of 
gp41, an HIV protein, are not correlated with severity of dementia in a 
postmortem analysis of patients with known dementia (Glass, Fedor, 
Wesselingh, & McArthur, 1995; Wesselingh, Glass, McArthur, Griffin, & Griffin, 
1994).  However, another study found that dementia was correlated with 
increased HIV positive cells of the brain regions associated with the symptoms 
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seen in the patients prior to death (Nuovo & Alfieri, 1996).  Interestingly, HIV 
does not infect neurons directly, and apoptosis of neurons that is seen in HIV is 
not associated with productive HIV infection in the brain (Adle-Biasette et al., 
1995).  It is apparent that there might be a correlational relationship between HIV 
levels in the brain and severity of symptoms, but it is not consistent and other 
components may play a much bigger role in the pathogenesis of neurocognitive 
impairments in HIV.   
One of the key components involved in causing neurocognitive impairment 
is the activation of the immune system in the brain.  Interactions between the 
immune system and the central nervous system have taken a prominent role in 
the mechanisms of pathology in neurocognitive impairments in HIV.  While HIV 
does not infect neurons directly, immune cells such as microglia/macrophages 
and astrocytes are well-known to be infected readily by HIV and are the likely 
culprits involved in bringing HIV into the brain (for review, see Eugenin & 
Berman, 2005).  Activated microglia/macrophages are correlated with severity of 
impairment in patients diagnosed with HIV-associated dementia (Glass, Fedor, 
Wesselingh, & McArthur, 1995; review, Kaul & Lipton, 2006).  Chronic activation 
of microglia may induce neurotoxic levels of release of proinflammatory cytokines 
such as tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β), as well as 
upregulation of products involved in the arachadonic acid cascade such as 
cyclooxygenase-2 (COX-2) and prostaglandin E2 (PGE2) (for review of 
neurotoxic effects of microglial activation, Block & Hong, 2005; Brune, 2003; 
Marchetti & Abbracchio, 2005).  Another product of microglial activation is 
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inducible nitric oxide (iNOS), which is responsible for release of large amounts of 
nitric oxide that can take on neurotoxic characteristics (Reynolds, Laurie, Mosley, 
& Gendelman, 2007; Snyder, 1993).    A number of these molecules are present 
in high levels in patients with HIV, and particularly in HIV positive patients with 
neurocognitive impairments.  For instance, one early study found increased 
levels of TNF-α and IL-1 in cerebrospinal fluid (CSF) and cortical tissue of HIV 
patients, but did not find an increase according to central nervous system 
symptoms (Tyor et al., 1992).  However, later studies have found differences in 
proinflammatory activity in those HIV positive patients with neurological 
symptoms and those with none.   Examination of RNA extracted from HIV 
positive patients diagnosed with dementia, vacuolar myelopathy (associated with 
motor symptoms), or neuropathy found increased levels of TNF-α, but there was 
no increase in TNF-α in HIV patients without neurological impairments 
(Wesselingh et al 1994).  CSF samples of HIV patients with neurological disease 
show increased PGE2, iNOS, TNF-α, and IL-1 that is correlated with severity of 
neurological disease (Griffin, Wesselingh, & McArthur, 1994; Perrella, Carrieri, 
Guarnaccia, & Soscia, 1992; Vincent et al., 1999).  HIV patients with encephalitis 
also show increased expression of IL-1β and iNOS (Zhau, Kim, Morgello, & Lee, 
2001).  Human astroglia and monocytes exposed to HIV in vitro also release 
toxic levels of IL-1β, TNF-α and products of the arachadonic acid cascade (Genis 
et al., 1992).  The high levels of these markers of inflammation indicate a chronic 
condition in the brain of HIV patients with neurological symptoms that could very 
well lead to apoptosis. 
 4
Indeed, these markers are found in colocalized with HIV positive cells in 
the brain, indicating that productive infection of microglia and astrocytes are 
causing the release of the proinflammatory mediators from the immune cells 
(Nuovo & Alfieri, 1996; Zhau et al.,  2001; Rostasy et al., 1999).  However, 
apoptosis of neurons does not occur immediately adjacent to these HIV positive 
cells, nor does it occur immediately after infection; instead, apoptosis only occurs 
after a delay of at least 1-2 weeks of infection, and the lack of immediate 
localization indicates the apoptosis is caused by soluble factors released by the 
infected cells (Shi et al., 1996).  These data indicate that apoptosis of neurons is 
caused indirectly through immune cell mediators. 
Collectively, these data indicate an increased, chronic inflammatory 
response in brains of HIV positive patients that is correlated with neuron loss 
associated with neurological impairments.  Unlike many of the hallmark 
symptoms of HIV/AIDS, neurological impairments in HIV are not associated with 
opportunistic infections, and evidence clearly points towards a fundamental part 
of HIV as being the stimulating factor of the cascade of actions that begins with 
activation of immune cells and ultimately induces apoptosis of neurons (for 
review, see Kaul & Lipton, 2001).  There is substantial evidence indicating that 
some of the nine proteins made by HIV are able to induce activation of immune 
cells.  Interestingly, actual productive infection by HIV is not necessary to 
produce cytokines such as IL-1 and TNF-α, supporting the possibility of HIV 
protein-induced immune activation (Merrill et al., 1992).  Although many proteins 
of HIV are implicated in these processes, tat and gp120 are the most studied.  
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For a review on Tat, see King, Eugenin, Buckner, and Berman (2006).  In vitro 
evidence from cultured human glial cultures produce IL-1, TNF-α, and nitric oxide 
when exposed to gp120, and gp120 induces death in human neuroblastoma cells 
and rat striatal neurons (Corasaniti et al., 1995; Koka et al., 1995; Singh et al., 
2004).  Oxidative stress is another factor that may induce apoptosis by gp120 
(Jana & Pahan, 2004).   
HIV/AIDS and Neurological Complications: Experimental Evidence (In Vivo 
and In Vitro)  
Injection of gp120 into the lateral ventricles of rats has become a common 
experimental model of neurological effects of HIV in the brain (for review, see 
Brenneman, McCune, Mervis, & Hill, 1994; Corasaniti et al., 2001).  Daily 
intravcerebroventricular injections of gp120 up to 14 days caused an increase in 
COX-2, PGE2, and IL-1β in brain tissue as well as neuronal apoptosis, which 
was reversed by COX-2 inhibitor indomethacin or an IL-1β converting enzyme 
inhibitor (Bagetto, et al., 1995; Bagetta, et al., 1996; Bagetta, et al., 1996; 
Bagetta et al., 1998; Bagetta et al., 1999; Barak et al.,  2002; Maccorrone et al.,  
2000).  Injection of gp120 into the rat striatum produces a decrease in brain-
derived neurotrophic factor (BDNF) and glial-derived neurotrphic factor (GDNF) 
and a loss of dopaminergic neurons in the striatum and substantia nigra; 
pretreatment with a BDNF viral vector prevented neuronal loss (Nosheny, 
Bachis, Acquas, & Mocchetti, 2004; Nosheny, Bachis, Aden, DeBernardi, & 
Mocchetti, 2006; Nosheny et al., 2007).   Gp120 also causes sickness behaviors 
such as fever, appetite loss and weight loss, and increased corticosterone 
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(Bagetta et al., 1999; Barak et al., 2002).  Due to these sickness behaviors, it is 
difficult to test more complex behaviors in rats administered gp120, but Pugh et 
al. found that administration of gp120 after contextual fear conditioning but prior 
to testing showed impairment in freezing response when compared to cued fear 
conditioning, which was correlated with increased levels of IL-1β in the frontal 
cortex and hippocampus and prevented by IL-1β antagonists (Pugh et al., 2000).  
In addition to evidence gathered from intracerebral injections of gp120, a gp120 
transgenic mouse developed to express gp120 only in astrocytes show the 
neuronal damage produced by gp120 selectively in the brain are similar to those 
seen in HIV patients with neurological disease (Toggas et al., 1994).  Gp120 and 
the proinflammatory mediators induced by gp120 produce alterations in the blood 
brain barrier, which may also increase the viral load and potentiate inflammation 
and neurotoxicity further (for review, see Banks, Ercal, & Price, 2006).   
Opiates and HIV 
 The relationship between HIV and progression to AIDS in opiate users has 
long been hotly debated due to known immunosuppressive effects of opiates and 
the increased risk of HIV infection in heroin user populations (for review, see 
Grant, Sacktor, & McArthur, 2005).  However, the association between opiates 
and the development of neurological effects in HIV positive patients has been 
clearly supported.  HIV encephalitis and neuropathy, both conditions closely 
related to HIV-induced neurocognitive impairments, show increased prevalence 
in intravenous drug users (Bell, Brettle, Chiswok, & Simmonds, 1998; Davies et 
al., 1997; Morgello et al., 2004).  Interestingly, opiate abuse is the most 
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significant predictor of neuropathy among intravenous drug users (Morgello et al., 
2004).   
 The mechanism through which opiates may increase risk of developing 
neurocognitive impairments in HIV positive patients is still unclear.  However, 
much evidence points towards an additive effect of opiates on increasing 
proinflammatory cytokines and oxidative stress.  For instance, in intravenous 
drug users, microglia activation is increased in both HIV positive patients 
(compared HIV positive patients who were not intravenous drug users) and even 
in patients not infected with HIV (Arango, Simmonds, Brettle, & Bell, 2004; Bell et 
al., 2002). 
 The ability of opiates to be immunomodulatory is well known; however, the 
effects of opiates on the immune system vary wildly depending upon the 
conditions in which the drug is administered.  Opiates given peripherally will 
decrease immune response of T and B lymphocytes as well as natural killer cells 
(Roy, Charbonauer, & Barke, 1999; West, Lysle, & Dykstra, 1997; West, Dykstra, 
& Lysle, 1998).  The effects of opiates on proinflammatory cytokines is quite 
debatable as morphine has been shown to both increase and decrease IL-1 and 
TNF-α (for review, see Rogers & Peterson, 2003).  Morphine may also influence 
conditions to produce an environment in which infections will overstimulate the 
immune system; for example, morphine downregulates antiapoptotic proteins 
and increases proapoptotic proteins (Emeterio, Tramulla, & Hurle, 2006).  Other 
models of infection show that morphine alone does not usually produce 
cytotoxicity, but in combination with an immune system stimulator, morphine can 
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increase IL-1β, TNF-α, nitric oxide, and neuronal death (Chang, Felix, Jiang, & 
Fiala, 2001; Johnston et al., 2004; Kapasi, Gibbons, Mattana, & Singhai, 2000; 
review, Nath et al., 2002; Pacifi, diCarlos, Bacosi, Pichini, & Zuccaro, 2000).  In 
sum, opiates produce a destabilizing effect on immune function which can have 
opposite effects depending on conditions.  In particular, although opiates appear 
to suppress most peripheral immune functions, opiates can potentiate 
proinflammatory response in the central nervous system (for reviews, see Rogers 
& Peterson, 2003; Hauser et al., 2005).   
 In experimental models of HIV, opiates are also detrimental to neuronal 
health.  Neuronal/glial cultures exposed to gp120 and morphine showed an 
increase in cell death compared to cultures exposed to gp120 alone, and 
morphine had no effect by itself (Hu, Sheng, Lokensgard, & Peterson, 2005).  
Exposure of neuroblastoma, gliablastoma, and HIV-exposed macrophages 
combined with morphine also showed an increase in cytotoxicity and signs of 
oxidative stress (Koutsilieri et al., 1997).  Rhesus macaques dependent on 
morphine infected with simian immunodeficiency virus (SIV), a lentivirus similar 
to HIV that naturally infects non-human primates, showed a number of 
detrimental effects compared to those infected monkeys not dependent on 
morphine: increased replication rate of SIV, increased mutation of SIV and 
resistance to treatment, increased replication in the cerebral compartment 
(Chuang et al.,  2005; Kumar et al., 2004).   
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Present Experiments 
 Given the evidence of opiate interactions with HIV in the brain, the 
following experiments were undertaken to evaluate the effects of 
intracerebroventricular (icv) injections of gp120 and subcutaneous (sc) injections 
of heroin.  The purpose is to measure changes induced by gp120 and heroin 
alone and in combination in the expression of proinflammatory mediators at the 
messenger RNA (mRNA) in specific brain regions that are affected in HIV 
infection of the brain.   
 The first set of experiments (Experiments 1 and 2) were focused on 
chronic administration of gp120 and/or heroin for 7 or 8 days.   The first 
experiment was based on the methods of Bagetta et al. (1996) and sacrificed 
animals 24 hours after last treatment.  However, Bagetta et al. used 
immunohistochemistry to examine protein in the brain, while the present 
experiments were focused on mRNA levels.  For this reason, we performed a 
second experiment to examine effects of chronic gp120 and heroin on mRNA so 
that the animals were sacrificed 6 hours after last treatment, which is a timepoint 
that has proven successful in capturing mRNA cytokine changes in our 
laboratory for another model (lipopolysaccharide) of infection.  We hypothesized 
for these experiments that gp120 would increase mRNA expression of iNOS, IL-
1β, TNF-α, and COX-2, and that heroin would increase gp120-induced effects 
further while having no effect by itself.   
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 To further examine immediate effects of gp120 and heroin at various 
timepoints, the second set of experiments (Experiments 3 and 4) focused on 
acute effects of gp120 and heroin on brain mRNA of proinflammatory mediators.  
These experiments were important to help determine whether acute changes 
occur in mRNA expression of proinflammatory mediators that cannot be seen in 
a chronic model due to potential adaptive changes.  In these experiments, gp120 
and heroin were administered once and rats were sacrificed at 4, 6, and 8 hour in 
order to examine mRNA expression of iNOS, IL-1β, TNF-α, and COX-2 at 
various timepoints.  It was expected that gp120 would induce increased 
expression of these important proinflammatory molecules and heroin would 
potentiate these effects in combination with gp120.   
 The last experiment (Experiment 5) examined the effects of glycosylated 
gp120 in three doses: 0, 100ng, and 1µg.  The purpose of this experiment was to 
determine if glycosylation of gp120 has differential effects on expression of IL-1β 
and COX-2 as it has been shown that glycosylation may affect binding properties 
of gp120 (Li, Luo, Rasool, & Kang, 1993).  Glycosylated gp120 was administered 
in the same manner as previous experiments and rats were sacrificed at 2 and 6 
hours to provide two timepoints at which to evaluate mRNA expression of iNOS, 
IL-1β, and COX-2.    It was anticipated that glycosylation of gp120 would induce 
higher levels of iNOS, IL-1β, and COX-2 than artificial cerebrospinal fluid 
controls, and there would be a dose-dependent increase in mRNA expression of 
these immune factors. 
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 Collectively, these experiments examine the effects of chronic and acute 
gp120 and heroin on brain mRNA expression of the proinflammatory mediators 
iNOS, IL-1β, TNF-α, and COX-2.  An additional goal of this experiment is to 
examine brain region (cortex versus hippocampus) differences in mRNA 
expression of these vital immune molecules using RT-PCR.  Prior to these 
experiments, mRNA has not been measured in brain tissue in this laboratory.  
Successful measurement of brain tissue mRNA will provide a new avenue 
through which the neuroimmune functions may be measured.   
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II.  Methods 
All methods were approved by University of North Carolina at Chapel Hill’s 
Institutional Animal Care and Use Committee.  A total of 113 male Lewis rats (2-4 
months of age) were used for these experiments.  All animals were housed on a 
12:12 light:dark cycle in temperature-controlled DLAM-approved facility.  All 
experimental manipulations took place during the dark portion of the light cycle.  
Rats were allowed at least one week to habituate to the new environment prior to 
any experimental manipulations.  Food and water were available ad libitum.   
Surgical Procedures   
 Animals were anesthetized with a 1:1 mixture of ketamine/xylazine 
administered, i.p.  Anesthesia was monitored throughout surgery with toe-pinch.  
Rats were implanted with a 28 gauge 4.5mm length stainless steel guide cannula 
(Plastics One, Roanoke, VA).  Coordinates used for placement of unilateral left 
lateral ventricle were AP -0.90 and ML +1.5, DV flat to skull.  Coordinates used 
for placement in bilateral lateral ventricles were AP -0.90, ML +1.5, DV flat to 
skull and AP -0.90, ML -1.5, DV flat to skull.  Rats were allowed at least 5 days 
recovery time prior to any experimental procedures.  Gp120IIIB was obtained 
from Immunodiagnostics (Woburn, MA), glycosylated gp120IIIB was obtained 
from Advanced Biotechnologies (Columbia, MD) and diacetylmorphine (heroin) 
was obtained from National Institute of Drug Abuse (Bethesda, MD).     
Injections 
 Microinjections of gp120 (100ng or 1µg) and vehicle were performed with 
1µl, 5µl or 10µl Hamilton syringes at a volume of 1µl or 3µl.  These injections 
were performed manually over one minute, and injector was left in place for 30 
seconds more to allow for full dispersion.   
 Injections of heroin (1mg/kg or 3mg/kg) or saline were administered 
subcutaneously on the abdomen.   
Chronic Administration of Gp120 and Heroin 
Experiment 1.  Rats (n=12) were injected daily with gp120 (100ng) or bovine 
serum albumin (BSA) in a volume of 1µl and heroin (1mg/kg) or saline daily for 7 
days.  Rats were sacrificed 24 hours after last injection.   
Experiment 2.  Rats (n=12) were given a higher dose of gp120 (1µg) or BSA in a 
volume of 1µl and heroin (1mg/kg) or saline daily for 8 days.  Animals were then 
sacrificed 6 hours after last injections, based on previous mRNA analyses in the 
laboratory using other models of infection. 
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Acute Administration of Gp120 and Heroin 
Experiment 3.  Rats (n=28) were tested for acute responses to a one-time dose 
of gp120 (1µg) or BSA vehicle in a volume of 3µl and heroin (1mg/kg) or saline.  
Sacrifice was performed at 6 hours after injections. 
Experiment 4.  Rats (n=33) were administered a one-time injection of gp120 
(1µg) or BSA in a volume of 3µl and heroin (1mg/kg) or saline.  Sacrifice was 
performed at 4 or 8 hours after injections. 
Acute Administration of Glycosylated Gp120 
Experiment 5.  Rats (n=25) were given injections of glycosylated gp120 diluted in 
artificial cerebrospinal fluid in doses of 0, 100ng, or 1µg.  Animals were sacrificed 
2 or 6 hours after microinjection treatment. 
Sacrifice and Tissue Treatment 
 All rats were sacrificed using cervical dislocation to preserve 
immunological and neurochemical integrity. Brains were rapidly removed from 
the skull and dissected for hippocampus and cortex.  Tissues were processed for 
extraction of RNA using TriReagent (Molecular Research Company, Cincinnati, 
OH).  Complimentary DNA was created using the Clontech Advantage RT-for-
PCR kit (Mountain View, CA).  Polymerase chain reaction (PCR) was performed 
using Master Fast Start SYBR Green I kit (Roche, Indianapolis, IN) in a 
LightCycler 2.0 using LightCycler 4.0 software (Roche, Indianapolis, IN).  Primer 
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and protocol information regarding the specific molecules examined (GAPDH, 
iNOS, IL-1β, TNF-α, COX-2) can be found in Table 1.   
Table 1.  RT-PCR primer sequences and treatment.
Target Primer Sequence Cycles Anneal C°
GAPDH 3'  gtgcagcgaactttattga 5'  tccaaggagtaagaaaccc 30 58
iNOS 3'  gatgttgtagcgctgtgtgtca 5'  acaacaggaacctaccagctca 40 62
IL-1β 3'  ctctgcttgagaggtgctgatgta 5'  gaagctgtggcagctacctatgtct 40 63
TNF-α 3'  cagccttgtcccttgaagagaacc 5'  tactgaacttcggggtgattggtcc 40 63
COX-2 3'  cagtattgaggagaacagatggg 5'  tacaagcagtggcaaaggcc 40 62
  
Statistical Treatment 
All statistics were analyzed using SPSS 15.0 (Chicago, Illinois).  Effects with a p 
value of 0.05 or less indicate a significant effect.  Trends or effects approaching 
significance were reported for effects with a p value between 0.05 and 0.075.  
Posthoc tests (Tukey) or a priori t-tests, if applicable, were run to determine 
group differences if the ANOVA indicated a significant main effect or interaction.  
Non-significant results are not reported. If rats were recorded as having abnormal 
behavioral responses and data from the same rat was identified as outliers as 
determined by Grubb’s test, this data was removed from the dataset prior to 
analysis.   
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III.  Results 
Housekeeping Gene 
All samples had glyceraldehyde-3-phosphate dehydrogenase (GAPDH) levels 
quantified by RT-PCR and groups were determined to be not statistically different 
in GAPDH expression prior to the quantification of any other molecules.  Any 
samples that showed evidence of primer dimers as determined by melting peak 
analysis were not included in analyses.   
Chronic Administration of Gp120 and Heroin 
Experiment 1.  RT-PCR successfully detected iNOS, IL-1β, and COX-2 in the 
hippocampus and cortex samples.  TNF-α was detected but was not measurable 
due to primer dimer contamination.  Statistical analysis was run using a 2 
(gp120) X 2 (heroin) X 2 (brain region) analysis of variance (ANOVA).  The 
analysis yielded a significant interaction for gp120 X heroin on iNOS, F (1, 12) = 
7.199, p=0.020 (Figure 1A).  No significant effects of gp120, heroin, or brain 
region were found in IL-1β or COX-2 (Figures 1B & 1C).  TNF-α analysis 
revealed high levels of primer dimers and was not used. 
  
Figure 1. Mean (+/- SEM) mRNA levels of iNOS, IL-1β, and COX-2 as measured 
by RT-PCR.  Rats were administered icv gp120 (100ng) or BSA and 
subcutaneous heroin (1mg/kg) or saline daily for 7 days and sacrificed 24 hours 
after last treatment. 
18 
  
Experiment 2.  Statistical analysis was run using a 2 (gp120) X 2 (heroin) X 2 
(brain region) ANOVA.  For this experiment, there were no significant effects of 
heroin or gp120 in iNOS (Figure 2A) or IL-1β (Figure 2B).  However, the effect of 
gp120 on mRNA of iNOS approached significance, F (1, 14) = 3.798, p=0.072.  
Brain region differences were found in mRNA of IL-1β, F (1, 12) = 4.799, 
p=0.049, and approached significance in mRNA levels of iNOS, F (1, 14) = 
3.898, p=0.068.  Analyses did not reveal any significant effects of gp120, heroin, 
brain region, or any interactions of the three on TNF-α and COX-2 mRNA 
(Figures 2C & 2D). 
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Figure 2.  Mean (+/- SEM) mRNA levels of iNOS, IL-1β, TNF-α and COX-2 as 
measured by RT-PCR.  Rats were administered icv gp120 (1µg) or BSA and 
subcutaneous heroin (1mg/kg) or saline daily for 8 days and sacrificed 6 hours 
after last treatment. 
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 Acute Administration of Gp120 and Heroin 
Experiment 3.  Statistical analysis was run using a 2 (gp120) X 2 (heroin) X 2 
(brain region) ANOVA.  For this experiment, significant effects of gp120 were 
found in mRNA levels of both iNOS, F (1, 34) = 4.387, p=.044 (Figure 3A) and IL-
1β, F (1, 44) = 8.481, p=0.006 (Figure 3B).  An additional interactive effect 
between gp120 and heroin on iNOS mRNA was present, F (1, 34) = 7.271, 
p=0.011.  Posthoc Tukey’s tests showed iNOS mRNA measured in Group 4 
(heroin/gp120) differed from Groups 2 (heroin/BSA) and 3 (saline/gp120), but not 
from Group 1 (saline/BSA).  The heroin/gp120 group also showed significantly 
increased IL-1β mRNA compared to saline/BSA (t (14.11) = -2.938, p=0.011), 
heroin/BSA (t (15.29) = -2.852, p=0.012), and saline/gp120 (t (15.169) = -2.333, 
p=0.034) groups, which did not differ from each other.  The effect of heroin on IL-
1β mRNA approached significance, F (1, 44) = 3.932, p=0.054, as did the 
interaction of heroin and gp120, F (1, 44) = 3.832, p=0.057.  The effect of gp120 
approached significance in expression of TNF=α, F (1, 44) = 3.485, p=0.069 
(Figure 3C).   COX-2 mRNA was successfully measured and revealed only a 
trend towards brain region differences, F (1, 41) = 3.688, p=0.062.   
Experiment 4.  Statistical analysis was performed using a 2 (gp120) X 2 (heroin) 
X 2 (time point) X 2 (brain region) ANOVA for each molecule.  For this 
experiment, no significant effects of heroin or gp120 were found for iNOS (Figure 
4A) or IL-1β (Figure 4B).  There was, however, a significant difference shown 
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between brain regions for IL-1β, F (1, 35) = 10.842, p=0.002.  TNF-α mRNA 
levels were not measurable due to primer dimers.   
Figure 3.  Mean (+/- SEM) mRNA levels of iNOS, IL-1β, TNF-α and COX-2 as 
measured by RT-PCR.  Rats were administered icv gp120 (1µg) or BSA and 
subcutaneous heroin (1mg/kg) or saline once and sacrificed 6 hours after 
treatment. 
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Figure 4.  Mean (+/- SEM) mRNA levels of iNOS and IL-1β as measured by RT-
PCR.  Rats were administered icv gp120 (1µg) or BSA and subcutaneous heroin 
(1mg/kg) or saline once and sacrificed 4 or 8 hours after treatment. 
 25
 Acute Administration of Glycosylated Gp120 
 Experiment 5.  Statistical analysis was run using a 2 (timepoint) X 2 (brain 
region) X 3 (gp120) ANOVA.  The analysis revealed no significant effects of 
gp120 on IL-1β at 2 hours or 6 hours (Figure 5A & 5B) or COX-2 at 2 hours and 6 
hours (Figure 5C & 5D).  A significant brain region difference was detected for 
both COX-2, F (1, 38) = 51.595, p=0.000, and IL-1β, F (1, 37) = 5.581, p=0.024.  
TNF-α and iNOS were not measurable due to high levels of primer dimers.  
However, there was a significant difference between 0 and 100ng of gp120, t 
(4.14) = -2.814, p=0.046 at 2 hours for IL-1β as revealed by two-tailed t-test.   
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Figure 5.  Mean (+/- SEM) mRNA levels of IL-1β and COX-2 as measured by 
RT-PCR.  Rats were administered icv glycosylated gp120 (0, 100ng, or 1µg) 
sacrificed 2 (5A and 5C) or 6 (5B and 5D) hours after treatment. 
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 Table 2.  Means and Standard Error of Mean (SEM) for Experiment 1.       
      7 days of treatment, sacrificed 24 hours after last treatment. 
  
 
Treatment     iNOS IL-1β     TNF-α   COX-2   
    n      Mean SEM n Mean SEM n Mean SEM n Mean SEM
saline/BSA hippocampus   2 830.66 803.68 3 11875.11 5144.79 . n/a   3 5933.33 339.23
  cortex 3 3589.98 2741.46 3 9464.22 3984.87      3 4873.33 670.36
                           
heroin/BSA hippocampus 2 11795 3641.67 2 8148.33 4118.33   n/a   3 8535 5065
  cortex 2 7794.1667 4699.17 2 4888.33 3474.5      3 4136 3474
                           
saline/gp120 hippocampus 3 8540.56 3509.3 1 14073.33 n/a   n/a   3 4733 376.756
  cortex 3 5951.34 3044.68 1 2039.67 n/a      3 4443 986.6
                           
heroin/gp120 hippocampus 3 716 143.27 2 6713.67 3499.67   n/a   3 5030 830.72
  cortex 2 5028.5 4298.17 3 3404.44 565.32      3 2406 1127.96
               
Table 3.  Means and SEM for Experiment 2.         
      
 
 
8 days of treatment, sacrificed 6 hours after last treatment. 
 
 
Treatment     iNOS IL-1β     TNF-α   COX-2   
    n      Mean SEM n Mean SEM n Mean SEM n Mean SEM
saline/BSA hippocampus   3 313.57 230.99 3 1830.33 629.87 3 367.32 64.03 3 384.33 86.19
  cortex 3 89.63 23.68 3 659.77 224.74  3 275.48 66.57 3 360.33 31.93
                            
heroin/BSA hippocampus   3 1230.03 857.77 3 3628.22 1885.62 3 359.1 152.89 2 484.5 32.5
  cortex 3 168.33 14.45 3 388.01 305.55  3 585.33 483.67 3 301 92.34
                            
saline/gp120 hippocampus   2 1508.48 1501.52 1 4446.67 n/a 1 714.67 n/a 1 468 n/a
  cortex 2 770.37 769.63 1 373.33 n/a  1 597.67 n/a 1 289 n/a
                            
heroin/gp120 hippocampus   3 2717.33 1137.85 3 3534.33 1975.37 3 910 314.21 3 350 24.5
  cortex 3 747.33 386.04 3 2773.33 582.64  3 427.922 58.1 3 317 81.15
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 Table 4.  Means and SEM for Experiment 2.        
     
      
       
  
1 day of treatment, sacrificed 6 hours after last treatment. 
    
  
   
 
 
Treatment     iNOS IL-1β TNF-α COX-2   
    n Mean        SEM n Mean SEM n Mean SEM n Mean SEM
saline/BSA                           
  hippocampus   6 2341.89 262 6 799.72 270.05 6 252.62 70.05 6 2771.67 373.47
  cortex 6 2478.72 186.88 6 676.07 340.3 6 189.28 53.36 6 2391 558.88
heroin/BSA                           
  hippocampus   5 1374.8 361.45 6 573.06 200.76 6 172.74 63.31 4 2739.75 615.27
  cortex 3 2331.78 387.85 6 930.56 566.04 6 242.03 101.14 6 2251.67 294.18
saline/gp120                           
  hippocampus   4 1915.42 526.86 7 1575 473.13 7 321.67 103.37 6 3225 311.44
  cortex 4 2374 306.19 7 946.9 175.67 7 320.08 123.82 7 2852.71 301.83
heroin/gp120                          
  hippocampus   5 3862.07 1059.08 7 3277.05 1287.05 7 358.29 158.08 7 3677.14 652.08
  cortex 5 2833.93 1083.23 7 3562.14 1326.48 7 371.89 147.55 7 2298.57 315.28
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Table 5.  Means and SEM for Experiment 4.    
        
1 day of treatment, sacrificed 4 hours after last treatment. 
        
Treatment     iNOS   IL-1β   
    n Mean SEM n Mean SEM 
saline/BSA               
  hippocampus 4 11934.00 7092.71 4 9329.00 4505.02 
  cortex   5984.50 5215.50 3 3874.67 1803.59 
heroin/BSA               
  hippocampus 3 7630.00 3228.51 3 7840.00 2783.17 
  cortex   9422.50 6111.56 4 6759.50 4810.50 
saline/gp120               
  hippocampus 4 1512.50 4150.42 4 17755.00 7070.90 
  cortex   4232.50 153.21 4 3612.50 599.02 
heroin/gp120               
  hippocampus 4 506.75 93.82 5 5096.40 3463.73 
  cortex   3468.60 3037.71 5 2217.32 1223.80 
          
1 day of treatment, sacrificed 8 hours after last treatment. 
        
Treatment     iNOS   IL-1β   
    n Mean SEM n Mean SEM 
saline/BSA               
  cortex 2 8260.00 3440.00 4 511.65 256.24 
heroin/BSA              
  cortex 3 19666.00 9079.26 4 2062.50 1125.37 
saline/gp120               
  cortex 1 2670.00 n/a 4 843.25 247.93 
heroin/gp120               
  cortex 2 3845.00 2605.00 4 660.50 360.22 
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Table 6.  Means and SEM for Experiment 5.    
        
1 day of treatment, sacrificed 2 hours after last treatment. 
        
Treatment     IL-1β   COX-2   
    n Mean SEM n Mean SEM 
0.0 gp120               
  hippocampus 4 19298.58 16895.65 4 7622.50 3181.33 
  cortex 4 4113.70 2993.02 4 313.78 76.80 
100ng gp120               
  hippocampus 4 3521.00 1817.16 4 9935.00 3795.49 
  cortex 4 24817.50 6719.97 4 664.25 147.62 
1µg gp120               
  hippocampus 4 1893.25 660.21 4 4860.00 911.33 
  cortex 4 11305.00 5188.55 4 256.53 83.78 
          
1 day of treatment, sacrificed 6 hours after last treatment. 
        
Treatment     IL-1β   COX-2   
    n Mean SEM n Mean SEM 
0.0 gp120               
  hippocampus 4 4239.25 2766.92 4 5375.00 166.86 
  cortex 4 15567.50 11587.59 4 339.25 15.00 
100ng gp120               
  hippocampus 4 3988.83 3509.36 4 3630.00 229.56 
  cortex 4 22623.25 21140.07 4 332.75 82.41 
1µg gp120               
  hippocampus 4 4006.40 2527.02 4 5764.00 522.54 
  cortex 4 3401.60 1972.22 4 262.82 100.18 
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IV. Discussion 
Significant and Marginal Effects 
The results of these experiments show a collection of interesting effects of 
gp120, heroin, and brain regions on mRNA expression of the proinflammatory 
mediators iNOS, IL-1β, TNF-α, and COX-2.  These data established a precedent 
to perform RT-PCR on immune mediators in the brain, which has never been 
done before in this laboratory.  The data also help to establish experimental 
protocols in determining effects of chronic and acute administration of gp120 and 
heroin alone and together on expression of immune mediators in the brain.   
Experiment 1 was modeled after the findings that 7 days of gp120 icv 
injections caused an increase in IL-1β and COX-2 in when rats were sacrificed 
24 hours after the last treatment (Bagetta et al., 1998; Bagetta et al., 1999).  
However, Bagetta et al. used immunohistochemistry to stain for the protein of IL-
1β and COX-2; the present experiment examined the expression of IL-1β and 
COX-2 messenger RNA.  The changes in mRNA expression may very well occur 
at different time points than that of protein, and it is likely that with this study, the 
time point of sacrificing 24 hours after last treatment simply missed the 
appropriate time for measuring mRNA expression.  Given the interaction effect of  
gp120 and heroin to decrease expression of iNOS, it may be possible that 
adaptive changes had already occurred in this group, and mRNA of iNOS was 
being downregulated to adapt to a previous increase prior to the 24 hour sacrifice 
timepoint.  These effects may also been seen in IL-1β with less variability and a 
larger sample size.  However, these experiments did not address this possibility, 
and this may be a potential avenue of future research, in order to determine if 
perhaps heroin alters the timeline of gp120-induced changes in iNOS expression 
in mRNA.   
Brain tissue of rats administered gp120 or BSA and heroin or saline for 8 
days and sacrificed 6 hours after the last treatment showed a significant 
difference only in expression of IL-1β in brain regions.  This time point was 
chosen because previous studies in our laboratory have found effects in mRNA 
of other tissues after a systemic immune challenge.  In particular, cortex tissue 
showed an increase when gp120 and heroin were combined, but the 
hippocampus did not show this effect.  These results are intriguing, and may 
represent a mechanism through which heroin may acutely disrupt potential 
adaptive changes affecting IL-1β mRNA after chronic gp120 exposure.  There 
were also a few notable trends in the analysis of iNOS mRNA.  The marginally 
significant effects of gp120 and heroin suggest that with a higher sample number, 
these effects may play out to be significant.   
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The aim of the acute gp120 and heroin experiments were to observe any 
effects that occur immediately after the first injection of gp120 and heroin.  These 
effects were important to assess in light of our findings of possible adaptations 
occurring in chronic gp120 and heroin: no effect at 24 hours after last treatment 
and increases only in heroin and gp120-treated rats when sacrificed 6 hours 
post-treatment.  These findings suggested that heroin may either increase the 
length at which gp120 has an effect, or may alter it and increase it altogether.   
Experiment 3, in which rats were administered gp120 or BSA and heroin 
or saline once and sacrificed 6 hours later, showed significant effects and a few 
important trends. INOS presented the most robust findings, with a main effect of 
gp120 and an interaction between gp120 and heroin being clearly seen.  Posthoc 
tests revealed that the effects lie primarily in increased expression of iNOS in 
group 4 (gp120/heroin).  The significant effect of gp120 and the marginally 
significant effect of heroin on expression of IL-1β mRNA also indicate the 
importance of heroin on the acute effects of gp120.  As seen in iNOS, IL-1β 
mRNA levels for group 4 (gp120/heroin) are significantly different from all other 
treatments.  The fact that gp120 by itself was not altered may represent an 
alternate pathway through which heroin may have unique effects on the 
proinflammatory mediators; that is, gp120 may primarily affect proinflammatory 
proteins through other pathways (such as through infiltrating lymphocytes from 
the peripheral or stores of uncleaved protein), but when combined with heroin, 
may also affect mRNA expression.  The trend of TNF-α mRNA expression to 
increase with the administration of heroin is something that will be examined 
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more closely in future studies.  TNF-α is one of the most prominent cytokines 
implicated in neurological complications of HIV (Tyor et al., 1993; Wesselingh et 
al., 1994), and it is not clear from these results if heroin also plays a role in this 
important molecule as is seen in iNOS and IL-1β.   
To further examine the time course of the acute effects of heroin and 
gp120, gp120 or BSA and heroin or saline were administered once to rats with 
sacrifice occurring 4 or 8 hours after treatment.  The lack of significant effects of 
heroin or gp120 on IL-1β or iNOS could be explained by a number of factors.  
The most obvious explanation would be that the increases seen in Experiment 3 
are transient and are most measurable at 6 hours post-treatment.  Considering 
the very specific time frame in which mRNA increases are seen in other models 
of inflammation, increases easily seen only at 6 hours would not be surprising.  In 
order to assess smaller effects, a larger sample size would be required to fully 
evaluate the specific time frame in which gp120 and heroin affect mRNA 
expression of proinflammatory mediators.   
It has been reported that the posttranscriptional modification of 
glycosylation is necessary for gp120 to bind to human CD4 receptors (Li et al., 
1993).  However, this same report indicates that inflammatory responses can be 
induced without the binding of the CD4 receptor.  In order to address these 
concerns, the last experiment in this series administered glycosylated gp120 in 0, 
100ng, and 1µg doses.  This experiment was undertaken in order to assess 
whether glycosylated gp120 differed in its effects on expression of iNOS, IL-1β, 
TNF-α, and COX-2 mRNA.  However, due to primer dimer complications, iNOS 
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and TNF-α were not measurable.  IL-1β showed a significant increase at a dose 
of 100ng for brain tissue collected two hours after treatment; however, this effect 
was not seen at 6 hours.  However, the variability in the 100ng/6 hour treatment 
was substantial and may have obscured any significant effects.  Administration of 
1µg of glycosylated gp120 showed no effects on IL-1β mRNA expression at 
either 2 hours or 6 hours.  The reasons for this are unclear, but consistent with 
previous experiments (Experiments 3 & 4) in which (unglycosylated) gp120 at the 
same dose did not cause any increases in IL-1β mRNA by itself at 4, 6, or 8 
hours post-treatment.  It would seem, then, that glycosylation of gp120 may not 
necessary in this particular model of HIV effects in the brain (gp120 administered 
icv).   
While none of the experiments showed effects of gp120 or heroin on 
COX-2, there were some very interesting findings regarding mRNA expression of 
COX-2 in the brain.  Brain region differences showing increased levels of 
expression of COX-2 in the hippocampus were seen in 3 of the 5 experiments 
(Experiments 3-5), and the experiments that did not reach significantly different 
expression levels between brain regions consistently had higher means of COX-
2 expression in the hippocampus compared to the cortex (Experiments 1-2).  
While no effects of heroin or gp120 were seen in COX-2, these data are 
important for establishing parameters for future studies.  
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Potential Explanations for Marginal Effects 
 There are a number of significant results in these experiments, as well as 
a number of trends (p=0.05 to p=0.075) that are reported.  These trends are 
reported due to their importance when considered in context.  For experiments 
measuring immunological effects in the past, this laboratory has often used 
samples of 4 to achieve sufficient statistical power.  It was based on this 
knowledge that the experiments were designed with samples of 3 or 4- it was 
expected that these relatively low sample numbers would be able to show the 
robust effects expected in these experiments.  However, there were a number of 
factors that may have caused a low sample size to become a confound in the 
statistical analysis. 
The method of detection used in these experiments, SYBR Green I, has 
been useful in the past in this laboratory for detecting tissues taken from 
peripheral organs such as spleen, lung, and liver.  However, measuring 
expression of mRNA in brain tissue is something new altogether for this 
laboratory, and problems with primer dimer complications were encountered. The 
primer dimers are most likely due to low levels of these mediators present in the 
brain, and are not due to contamination because diluted purified standards also 
show primer dimers in the molecules that are prone to this (specifically, iNOS 
and TNF-α).  This is a problem that has been encountered in other laboratories 
for other molecules, and one method that has been successfully used to solve 
the problem of primer dimers is the use of the Universal Probe Library (UPL) 
method of detection for RT-PCR (Bakker, 2006).  While the SYBR Green I 
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method of detection causes fluorescence to be measured for any double-
stranded DNA, the UPL method of detection utilizes the fluorescence of only 
sequence specific probes that are bound, thus eliminating primer dimers from the 
analysis (Bakker, 2006; manufacturer information). The laboratory is currently 
transitioning to using UPL for RT-PCR with the expectations that this will solve 
the primer dimer problems and allow for more precise and greater statistical 
analysis.  Despite the difficulty with primer dimers, the results from these 
experiments were sufficient to provide data that will serve as a reference for 
future studies in our laboratory.   
Additionally, the strain from which the gp120 used in these experiments is 
derived from is important to consider.  HIV gp120 binds to human CD4 receptors, 
which causes a conformational change in the gp120 which allows it to bind to 
one of the chemokine receptors, CCR5 or CXCR4 (Deng et al., 1996; Feng, 
Broder, Kennedy, & Berger, 1996).  Which chemokine receptor the gp120 
preferentially binds to is how the strain is described; that is, those that bind to 
CCR5 are called R5 and those that bind to CXCR4 are called X4.  Most HIV 
patients are infected with R5 strains, but up to 50% of these patients go on to 
develop X4 strains, which are associated with progression to AIDS, increased 
neurotoxicity, and increased depletion of T cells (Gorry, Churchill, Crowe, 
Cunningham, & Gabuzda, 2005; Moore, Kitchen, Pugach, & Zack, 2004; Kaul & 
Lipton, 2004; Philpott, 2003).  The gp120 used in this study is gp120IIIB, which is 
derived from a primarily X4 strain of HIV. It was felt that an X4-derived gp120 
would be more appropriate, as cognitive deficits and related neuroinflammation is 
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usually seen at the later stages of AIDS that correlate with the development of X4 
HIV (Dunfee et al., 2006; Philpott, 2003; van de Bovenkamp, Nottet, & Pereira, 
2002).  Although R5 strains are usually present in the brain first, it is X4 that is 
more commonly associated with cognitive impairments (for review, Dunfee et al., 
2006).   
Coreceptor Alterations Induced by Opiates: A Potential Mechanism for 
Interactions of Gp120 and Heroin 
The mechanism through which opiates and gp120 may interact to produce 
increase inflammatory mediators is not clear at this point in time.  One possible 
explanation is that opiates may alter receptor expression of the gp120 
coreceptors.  Experimental studies have shown that opiates such as morphine 
and DAMGO upregulate CCR5 expression and downregulate natural ligands to 
CCR5, which may be due to heterodimerization of the µ-opioid receptor and 
CCR5 (Chen et al., 2004; Suzuki, Chang, Yau, Doi, & Chuang, 2002; for review, 
see Vallejo, de Leon-Casasola, & Benyamin, 2004).  Infection of SIV in rhesus 
macaques is mediated through CCR5, and those monkeys exposed to morphine 
show increased replication rate, mutation and resistance to AZT, increased 
expression of CCR5, increased susceptibility to SIV, and decreased natural 
ligands of CCR5 (Chuang et al., 2005; Guo, et al., 2002; Miyagi et al., 2000).  
The evidence for CXCR4 and opiate interactions is less compelling, with some 
results indicating morphine causes an upregulation in replication of only R5, 
although in vitro human immune cells treated with µ agonist DAMGO upregulated 
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both CCR5 and CXCR4, and pretreatment with DAMGO increased replication of 
both types of HIV strains (Guo et al., 2002; Steele, Henderson, & Rogers, 2003).   
Future Directions 
A future study to follow up on these experiments will examine the effects 
of opiates in combination with gp120 on the expression of CXCR4 and CCR5 in 
order to further examine the mechanism through which opiates alter gp120-
induced effects in the brain.   
Another future study would involve a comparison of protein and mRNA 
effects.  Recently published data has emerged that shows no effect of 
intracerebroventricular injection of gp120 (100ng) on mRNA of IL-1β in adult rats, 
which is consistent with our results (Abraham et al., 2008).  Most published data 
using the icv gp120 model in rats has only measured protein using 
immunohistochemistry (Bagetta et al., 1998; Bagetta et al., 1999).  However, 
immunohistochemistry is notoriously difficult to quantify.  To better address the 
differences between mRNA expression and protein expression, Western blots 
and available Enzyme-Linked Immunosorbent Assay (ELISA) assays will be 
employed to measure protein in specific brain regions.  Preliminary evidence is 
currently being measured in our laboratory indicates that although TNF-α mRNA 
expression was not measurable (due to primer dimers) when rats were given icv 
100ng gp120 and sacrificed at 2 or 6 hours, TNF-α protein expression in the 
hippocampus and cortex as measured by an ELISA shows significant increases 
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with gp120 administration.  This is encouraging evidence for more effects being 
drawn out through protein analysis. 
Summary 
 In summary, these experiments show a potentially unique interaction of 
heroin and gp120 on the mRNA expression of proinflammatory mediators such 
as iNOS and IL-1β that occur approximately 6 hours after treatment with heroin 
and gp120 in both chronic and acute models using icv administration of gp120.  
These data provide evidence that heroin and gp120 interact in a novel way that 
has not previously been in examined in mRNA in the brain.   
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